BioRestorative Therapies, Inc. (NASDAQ: BRTX) is currently working on an FDA Phase II clinical trial for their autologous stem-cell therapy, BRTX-100, to help patients who suffer from single-disc-related Chronic Lumbar Degenerative Disc Disease.<br /><br />Hear from expert, Dr. Jason Lipetz, MD, Physiatrist & Head of Spine Medicine at Northwell Health, as he discusses his work on those trials with BioRestorative Therapies in this must-see interview!<br /><br />BioRestorative Therapies was founded by scientists committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.
